+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib



Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib



Journal of Thoracic Oncology 4(8): 994-1001



Gaining a higher response rate (RR) has usually been determined as a primary end point in phase II trials evaluating the efficacy of new molecular targeted drugs. However, a relationship between clinical response and survival benefit has not been well studied in the patients treated with molecular targeted agents. Prospective trials of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) monotherapy in non-small cell lung cancer were extracted from MEDLINE, EMBASE, and the annual meetings in 2007 of the American Society of Clinical Oncology, European Cancer Conference, and World Conference on Lung Cancer. Correlation between clinical response and survival was examined using linear regression analysis. We also tried to compare the significance of RR as surrogate markers for survival with that of disease control rate (DCR) by calculating the area under their receiver operating characteristic (ROC) curves. We identified 24 phase II trials and 4 phase III trials with a total of 6171 patients and 30 treatment arms, including 22 arms for the gefitinib group and 8 arms for the erlotinib group. Both RR and DCR strongly correlated with median survival time (MST; p < 0.0001 and p = 0.003, respectively). In an ROC analysis, the area under the ROC curve predicting MST prolongation by RR was 0.918, which was higher than the area under the ROC curve by DCR. We found a significant relationship between RR and MST in clinical trials with EGFR-TKIs. RR could be an independent surrogate marker for MST in the current response criteria in the clinical trials of EGFR-TKIs.

(PDF emailed within 0-6 h: $19.90)

Accession: 055529720

Download citation: RISBibTeXText

PMID: 19633474

DOI: 10.1097/JTO.0b013e3181a94a2f


Related references

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clinical Cancer Research 12(13): 3908-3914, 2006

Prolonged survival of gefitinib treatment in patients with advanced and previously treated non-small cell lung cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(10): 1437-1440, 2006

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. British Journal of Cancer 96(8): 1191-1196, 2007

Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. Lung Cancer 100: 77-84, 2017

Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib. Journal of Thoracic Oncology 9(2): 200-204, 2014

Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 52(3): 373, 2006

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Experimental and Therapeutic Medicine 2(4): 685-693, 2011

Disease stabilization (SD) as a surrogate end-point in advanced non-small-cell lung cancer (NSCLC) patients treated with erlotinib (E) or gefitinib (G). 2007

Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. Journal of Thoracic Oncology 3(8): 912-914, 2008

Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). Journal of Thoracic Oncology 8(2): 229-237, 2013

Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Medical Journal 53(5): 931-939, 2013

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clinical Cancer Research 16(23): 5873-5882, 2011

Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials. Ai Zheng 28(6): 626-631, 2011

Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib. Journal of Cancer Research and Clinical Oncology 138(11): 1963-1969, 2013

Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer. Anti-Cancer Agents in Medicinal Chemistry 14(5): 646-650, 2014